What Is Compounded Liraglutide for Weight Loss?

What compounded liraglutide actually is

Liraglutide is a GLP-1 receptor agonist: an acylated form of human GLP-1 with 97% amino acid sequence homology to the natural hormone, stable against DPP-4 breakdown, with a plasma half-life of about 13 hours after subcutaneous injection. GLP-1 receptors sit in brain areas involved in appetite regulation, and liraglutide delays gastric emptying [1]. The roughly 13-hour half-life is the label's reason for daily dosing [1].

A compounded liraglutide product is liraglutide that a compounding pharmacy prepares rather than a manufacturer holding an FDA approval. FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed [3][4].

Is there an FDA-approved liraglutide for weight loss?

Yes. Saxenda is liraglutide 3 mg by daily injection, approved with a reduced-calorie diet and more physical activity to reduce excess body weight and maintain weight reduction long term. The label covers adults with obesity, adults with overweight plus at least one weight-related condition, and children 12 and older who weigh more than 60 kg and have obesity [1]. Generic liraglutide is also FDA-approved, including generics that carry the weight-management indication [2].

Victoza contains liraglutide but is a separate product: it is approved for type 2 diabetes in adults and children 10 and older and to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, at a maximum of 1.8 mg daily. It is not approved for weight loss [6]. The Saxenda label says not to combine it with other liraglutide products or with any other GLP-1 receptor agonist [1].

What liraglutide 3 mg did in trials

SCALE Obesity is the main weight-management study. It ran 56 weeks and enrolled 3,731 adults without type 2 diabetes, with a BMI of 30 or higher, or 27 or higher with treated or untreated dyslipidemia or hypertension. Participants received liraglutide 3 mg (2,487 people) or placebo (1,244), both with lifestyle counseling [7].

In the Saxenda label's analysis of that trial, body weight fell 7.4% with liraglutide versus 3.0% with placebo, a difference of 4.5 percentage points. At least 5% of body weight was lost by 62.3% versus 34.4%, and more than 10% by 33.9% versus 15.4% [1]. The published report gave 8.4 kg versus 2.8 kg using last-observation-carried-forward [7].

Two smaller trials add context. In SCALE Maintenance, 422 adults who had already lost at least 5% of weight on a low-calorie diet took 3 mg or placebo for 56 weeks and lost a further 6.2% versus 0.2%; 50.5% versus 21.8% lost another 5% or more [8]. In SCALE Diabetes, 846 adults with type 2 diabetes taking liraglutide 3 mg lost 6.0% of body weight versus 2.0% with placebo [9]. Among 251 adolescents aged 12 to 17, liraglutide lowered the BMI standard-deviation score by 0.22 more than placebo, and 43.3% versus 18.7% had a BMI reduction of at least 5% [10].

The cardiovascular outcomes trial for liraglutide, LEADER, used a 1.8 mg target dose in 9,340 adults with type 2 diabetes and high cardiovascular risk, not the 3 mg weight-management dose. Cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 13.0% versus 14.9% with placebo (hazard ratio 0.87) [11].

Dosing in the Saxenda label

The label starts at 0.6 mg once daily for one week, then increases weekly to 1.2 mg, 1.8 mg and 2.4 mg, reaching 3 mg daily from week 5. The 3 mg dose is the recommended adult dose; lower doses are for titration only. Injections go in the abdomen, thigh or upper arm at any time of day, with or without meals. The label says to check weight at 16 weeks and to stop if less than 4% of baseline body weight has been lost, and that if more than 3 days pass between doses, treatment restarts at 0.6 mg and steps up again [1].

These numbers come from Saxenda's FDA-approved label. A compounded product does not carry FDA-approved labeling [3].

What the Saxenda label warns about

The boxed warning: liraglutide caused dose- and duration-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures, and whether it causes them in humans is unknown. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1].

The Saxenda label warns about acute pancreatitis and says treatment should be discontinued if pancreatitis is suspected. Its other warnings cover acute gallbladder disease, hypoglycemia when combined with insulin or a sulfonylurea, a rise in heart rate, acute kidney injury from volume depletion, severe gastrointestinal reactions (it is not recommended in severe gastroparesis), serious hypersensitivity, and pulmonary aspiration during general anesthesia or deep sedation [1].

In the adult trials (3,384 people on Saxenda versus 1,941 on placebo, up to 56 weeks), nausea occurred in 39.3% versus 13.8%, diarrhea in 20.9% versus 9.9%, constipation in 19.4% versus 8.5% and vomiting in 15.7% versus 3.9%. About 68% versus 39% reported any gastrointestinal disorder, and 9.8% versus 4.3% stopped treatment because of side effects [1]. Among adults with type 2 diabetes also taking a sulfonylurea, glucose below 54 mg/dL occurred in 28.2% on Saxenda versus 12.7% on placebo [1]. Mean resting heart rate rose 2 to 3 beats per minute, and a rise above 10 bpm at two visits occurred in 34% versus 19% [1].

The label says to discontinue Saxenda when pregnancy is recognized; weight loss offers no benefit in pregnancy [1]. It no longer carries a suicidal behavior and ideation warning: FDA asked the makers of Saxenda, Wegovy and Zepbound to remove that language on 2026-01-13 after a review found no increased risk, and the current Saxenda label does not contain it [12][1].

Where the compounding rules stand for liraglutide

FDA says compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug [4].

On 2026-04-30 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the list of bulk substances that outsourcing facilities may compound with, finding no clinical need; comments were due 2026-06-29, and the agency said no final decision had been made [5].

FDA has also published handling concerns for compounded GLP-1 drugs: it recommends discarding a multi-dose vial 28 days after first use even if medication remains, using a new sterile needle and syringe for each dose, and not using an injectable GLP-1 drug that arrives warm or with inadequate refrigeration [4].

Where the efficacy and safety numbers come from

The weight-loss and side-effect figures on this page come from studies and labeling of FDA-approved liraglutide products: the weight-management studies used 3 mg, while the LEADER diabetes cardiovascular trial used a 1.8 mg target dose [7][11]. FDA notes that poor compounding practices can result in contamination or a product with too much or too little active ingredient [3].